Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on April 23, 2019. The report discloses a specific corporate event regarding preclinical research data rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a scientific announcement and does not contain financial statements or performance metrics.
Material Changes
There are no material financial changes reported versus a prior period. The material event disclosed is the release of preclinical data evaluating the combination of onvansertib with venetoclax in an AML cell model resistant to venetoclax.
Outlook, Risks, and Management Commentary
Management announced the preclinical data via a press release furnished as Exhibit 99.1. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the context of the scientific announcement.
Investor Verification Checklist
- Verify the registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Review Exhibit 99.1 (Press Release) for detailed preclinical data on onvansertib and venetoclax.
- Confirm the specific AML cell model used in the resistance study.
- Check subsequent filings for any clinical trial updates or financial impacts resulting from this data.